PITTSBURGH and HYDERABAD, India, Oct. 19, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its India-based subsidiary, Matrix Laboratories Limited, has formally changed its name to Mylan Laboratories Limited. The name change is effective immediately. Mylan announced its intention to rebrand Matrix as a Mylan company earlier this year.
Mylan Inc. Chairman and CEO Robert J. Coury said: "We are pleased to complete the name change from Matrix to a Mylan company and are excited to operate in India under one powerful brand. For the last 50 years, the Mylan name has stood for high quality products, unmatched reliability, outstanding customer service, unrelenting integrity, continuous innovation and serving unmet needs. Mylan's unwavering commitment to quality and long-standing track record of excellence set us apart from our competitors and will help to ensure our long-term success in India and around the world. We look forward to further educating customers, physicians, pharmacists and patients about the Mylan brand as we continue to grow our existing business and launch in the Indian commercial market in the coming months."
The name change has been approved by the Registrar of Companies in India. Mylan intends to retain the Matrix name for its institutional ARV franchise.
About Mylan Laboratories Limited
Mylan Laboratories Limited, founded as Matrix Laboratories Limited in 2001 in Hyderabad, India, is one of the world's largest manufacturers of low cost, high quality active pharmaceutical ingredients (API). Today, the company has a wide range of products, including those in the anti-asthmatic, antibacterial, antifungal, antiretroviral (ARV), cardiovascular, CNS, gastrointestinal and pain management segments. Mylan Laboratories also offers a growing line of finished dosage form products, predominantly generic ARV therapies for the treatment of HIV/AIDS, including both adult and pediatric therapies.
About Mylan Inc.
Mylan Inc., headquartered in Pittsburgh, Pa., ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.
SOURCE Mylan Inc.